Hong Kong Specialty Stores Stock News

SEHK:9999
SEHK:9999Entertainment

NetEase (SEHK:9999) Could Be 35% Undervalued As Earnings Beat Estimates

What changed at NetEase and why it matters for shareholders NetEase (SEHK:9999) recently approved a Third Amended and Restated Memorandum and Articles of Association at its 2026 Annual General Meeting, a governance update that helps frame how investors may view the stock’s latest move. The bylaw changes came shortly after NetEase stock gained 7.32% over the past week, following quarterly earnings of HK$4.03 per share versus an estimated HK$3.42, a 17.77% difference that has drawn fresh...
SEHK:788
SEHK:788Telecom

Is China Tower (SEHK:788) A Bargain After Its GSMA Move And AI Network Upgrade?

GSMA membership and AI focused network upgrade reshape the China Tower story China Tower (SEHK:788) has joined the GSMA and completed a nationwide upgrade that turns 5.6 million base stations and 2.1 million tower sites into intelligent edge computing hubs for connectivity in the AI era. See our latest analysis for China Tower. Despite the AI focused upgrade and GSMA membership, China Tower’s recent share price momentum has softened, with the stock at HK$9.04 and the 1 month share price...
SEHK:267
SEHK:267Industrials

Is CITIC (SEHK:267) Undervalued Following Its Final Dividend Announcement?

CITIC (SEHK:267) drew investor attention after its 26 June 2026 AGM, where the company declared a 2025 final dividend of RMB 0.385 per share, payable in either RMB or Hong Kong dollars. See our latest analysis for CITIC. While the 2025 final dividend announcement has focused attention on income, CITIC’s 1 month share price return is down 20.98% and the year to date share price return is down 13%, even as the 5 year total shareholder return of 83.56% points to a much stronger long term...
SEHK:2171
SEHK:2171Biotechs

CARsgen Therapeutics (SEHK:2171) Is Up 20.8% After First Solid Tumor CAR T Approval - What's Changed

CARsgen Therapeutics Holdings announced that China’s National Medical Products Administration has approved satricabtagene autoleucel (satri-cel), an autologous Claudin18.2-targeted CAR T-cell therapy, for Claudin18.2-positive, HER2-negative advanced gastric/gastroesophageal junction adenocarcinoma in patients who have failed at least two prior treatments. As the first CAR T-cell therapy approved globally for solid tumors, satri-cel could reshape treatment options in high-burden cancers like...
SEHK:2007
SEHK:2007Real Estate

Country Garden Holdings (SEHK:2007) Reports Weaker Sales, Is The Valuation Gap Justified?

Country Garden Holdings (SEHK:2007) has reported June contracted sales of about CN¥2.45b, down 13% year-on-year. The company also reported weaker first half sales and its first interest payment under a major offshore debt restructuring. See our latest analysis for Country Garden Holdings. The June sales update and progress on offshore debt restructuring come after a mixed price pattern for Country Garden Holdings, with the share price up 8.67% over one day and 10.59% over seven days, but down...
SEHK:2727
SEHK:2727Electrical

Shanghai Electric Group (SEHK:2727) Wins Arbitration As Fair Value Questions Remain

Shanghai Electric Group (SEHK:2727) is back in focus after the Singapore International Arbitration Centre dismissed all substantive claims brought by Oxagon Enterprises with prejudice, reducing legal overhang while leaving profit implications dependent on future enforcement. See our latest analysis for Shanghai Electric Group. Despite the legal win, Shanghai Electric Group’s recent 7 day share price return of 3.89% only partly offsets a 30 day share price decline of 15.98%. However, the 1...
SEHK:990
SEHK:990Trade Distributors

Deep Source Holdings (SEHK:990) Could Be 49% Undervalued After AGM Backing

AGM approvals put Deep Source Holdings in focus Deep Source Holdings (SEHK:990) is back on investors’ radar after shareholders approved new company bye laws, director re elections and refreshed share issue and repurchase mandates at the 30 June Annual General Meeting. See our latest analysis for Deep Source Holdings. Despite the supportive AGM outcome, Deep Source Holdings’ recent trading has been mixed. The 1 day share price return of 7.27% and 7 day share price return of 3.51% stand against...
SEHK:460
SEHK:460Pharmaceuticals

Sihuan Pharmaceutical Holdings Group (SEHK:460) Following Phase III Trial Progress Is The Stock Too Pricey

Sihuan Pharmaceutical Holdings Group (SEHK:460) recently reported that the first patient has been enrolled in a Phase III trial for Anaprazole Sodium Enteric-coated Tablets in Helicobacter pylori treatment, a development that could influence how investors view the stock. See our latest analysis for Sihuan Pharmaceutical Holdings Group. At a share price of HK$0.89, Sihuan Pharmaceutical Holdings Group has seen a 7-day share price return of 7.23%, but the 90-day share price return is down...
SEHK:175
SEHK:175Auto

Surging Exports And ZEEKR EV Growth Might Change The Case For Investing In Geely (SEHK:175)

In June 2026, Geely Automobile Holdings reported a 2% rise in total vehicle sales, powered by very large export growth and a 111% year-on-year jump in deliveries from its premium electric brand ZEEKR. This combination of stronger international demand and rapid electric vehicle momentum underscores how Geely is building a broader global footprint beyond its core China market. We’ll now explore how this surge in exports and ZEEKR’s rapid growth could influence Geely’s existing investment...
SEHK:2698
SEHK:2698Personal Products

July 2026's Asian Stocks Estimated Below Fair Value

As global markets navigate mixed economic signals and regional shifts, the Asian stock landscape presents intriguing opportunities for investors. With manufacturing resilience in China and improved sentiment in Japan, identifying undervalued stocks that could potentially benefit from these conditions is crucial for those looking to capitalize on the evolving market dynamics.
SEHK:1681
SEHK:1681Pharmaceuticals

Undiscovered Gems In Asia To Watch This July 2026

As global markets navigate mixed signals, with U.S. small-cap indices like the Russell 2000 experiencing declines and China's manufacturing sector showing resilience, investors are keenly observing Asia's evolving economic landscape. In this environment, identifying promising stocks often involves looking for companies that demonstrate strong fundamentals and adaptability to shifting market conditions.
SEHK:941
SEHK:941Wireless Telecom

CME Group Stock And Two Dividend Stocks Built For Steady Income

With inflation trends uneven across regions and central banks sending mixed signals on rate paths, dependable income can feel hard to find. That is where the Dividend Powerhouses screener comes in, focusing on companies with dividend yields above 5% that are covered by current earnings, growing and relatively stable. While policy debates continue around interest rates, growth and inflation, these stocks aim to put cash in your account today. In this article, you will see three stocks from the...
SEHK:2252
SEHK:2252Medical Equipment

Shanghai MicroPort MedBot (Group) (SEHK:2252) Wins EU CE Mark, Is The Valuation Already Too Rich?

Shanghai MicroPort MedBot (Group) (SEHK:2252) is in focus after its Toumai Remote laparoscopic surgery robot received the EU CE Mark, opening access to more than 30 European markets and providing formal regulatory recognition of remote surgery. See our latest analysis for Shanghai MicroPort MedBot (Group). The Toumai Remote CE Mark news comes as Shanghai MicroPort MedBot (Group)'s 1 day share price return of 1.57% and 7 day share price return of 4.20% contrast with weaker 30 and 90 day share...
SEHK:1357
SEHK:1357Interactive Media and Services

Asian Value Stocks Trading Below Estimated Fair Value

As global markets navigate a complex landscape marked by mixed performances in major indices and economic data, investors are increasingly turning their attention to Asia, where resilient manufacturing activity and strategic policy measures are shaping the investment climate. In this context, identifying undervalued stocks that trade below their estimated fair value can offer opportunities for those seeking to capitalize on potential market inefficiencies.